In conclusion, according to Kidney Disease Improving Global Outcomes guidelines (289), patients with osteoporosis and/or high fracture risk and CKD stages 1-3b with normal PTH should be treated similarly to the general population, whereas in CKD stages 3-5 and CKD-MBD, patients’ treatment should be individualized depending on biochemical indices and possibly bone biopsy results. The gene discussed is PTH; the disease is Marchiafava-Bignami disease.